Feasibility of Indirect Treatment Comparisons Between Niraparib Plus Abiraterone Acetate and Other First-Line Poly ADP-Ribose Polymerase Inhibitor Treatment Regimens for Patients with BRCA1/2 Mutation-Positive Metastatic Castration-Resistant Prostate Cancer

Maria De Santis, Sara Martínez Breijo, Paul Robinson, Camille Capone, Katie Pascoe, Suzy Van Sanden, Mahmoud Hashim, Marco Trevisan, Caitlin Daly, Friso Reitsma, Sophie van Beekhuizen, Haoyao Ruan, Bart Heeg, Elena Verzoni

Open source

DOI: 10.1007/s12325-024-02918-6
Published: 2024-07-03
Container: Advances in Therapy
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s12325-024-02918-6,
  title = {Feasibility of Indirect Treatment Comparisons Between Niraparib Plus Abiraterone Acetate and Other First-Line Poly ADP-Ribose Polymerase Inhibitor Treatment Regimens for Patients with BRCA1/2 Mutation-Positive Metastatic Castration-Resistant Prostate Cancer},
  author = {Maria De Santis and Sara Martínez Breijo and Paul Robinson and Camille Capone and Katie Pascoe and Suzy Van Sanden and Mahmoud Hashim and Marco Trevisan and Caitlin Daly and Friso Reitsma and Sophie van Beekhuizen and Haoyao Ruan and Bart Heeg and Elena Verzoni},
  year = {2024},
  journal = {Advances in Therapy},
  doi = {10.1007/s12325-024-02918-6},
  url = {https://doi.org/10.1007/s12325-024-02918-6}
}

RIS

TY  - JOUR
TI  - Feasibility of Indirect Treatment Comparisons Between Niraparib Plus Abiraterone Acetate and Other First-Line Poly ADP-Ribose Polymerase Inhibitor Treatment Regimens for Patients with BRCA1/2 Mutation-Positive Metastatic Castration-Resistant Prostate Cancer
AU  - Maria De Santis
AU  - Sara Martínez Breijo
AU  - Paul Robinson
AU  - Camille Capone
AU  - Katie Pascoe
AU  - Suzy Van Sanden
AU  - Mahmoud Hashim
AU  - Marco Trevisan
AU  - Caitlin Daly
AU  - Friso Reitsma
AU  - Sophie van Beekhuizen
AU  - Haoyao Ruan
AU  - Bart Heeg
AU  - Elena Verzoni
PY  - 2024
JO  - Advances in Therapy
DO  - 10.1007/s12325-024-02918-6
UR  - https://doi.org/10.1007/s12325-024-02918-6
ER  -

APA

Santis, M. D., Breijo, S. M., Robinson, P., Capone, C., Pascoe, K., Sanden, S. V., Hashim, M., Trevisan, M., Daly, C., Reitsma, F., Beekhuizen, S. V., Ruan, H., Heeg, B., & Verzoni, E. (2024). Feasibility of Indirect Treatment Comparisons Between Niraparib Plus Abiraterone Acetate and Other First-Line Poly ADP-Ribose Polymerase Inhibitor Treatment Regimens for Patients with BRCA1/2 Mutation-Positive Metastatic Castration-Resistant Prostate Cancer. Advances in Therapy. https://doi.org/10.1007/s12325-024-02918-6

Source records

crossref · retrieved 2026-11-10T20:07:39.875Z